Tarantini Francesco, Cumbo Cosimo, Anelli Luisa, Zagaria Antonella, Conserva Maria Rosa, Redavid Immacolata, Specchia Giorgina, Musto Pellegrino, Albano Francesco
Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy.
School of Medicine, University of Bari "Aldo Moro", Bari, Italy.
Front Pharmacol. 2022 May 23;13:906036. doi: 10.3389/fphar.2022.906036. eCollection 2022.
Since its introduction in clinical practice, eltrombopag (ELT) has demonstrated efficacy in heterogeneous clinical contexts, encompassing both benign and malignant diseases, thus leading researchers to make a more in-depth study of its mechanism of action. As a result, a growing body of evidence demonstrates that ELT displays many effects ranging from native thrombopoietin agonism to immunomodulation, anti-inflammatory, and metabolic properties. These features collectively explain ELT effectiveness in a broad spectrum of indications; moreover, they suggest that ELT could be effective in different, challenging clinical scenarios. We reviewed the extended ELT mechanism of action in various diseases, with the aim of further exploring its full potential and hypothesize new, fascinating indications.
自艾曲泊帕（ELT）引入临床实践以来，已在包括良性和恶性疾病在内的多种临床情况下显示出疗效，这促使研究人员对其作用机制进行更深入的研究。因此，越来越多的证据表明，ELT具有多种作用，从天然血小板生成素激动作用到免疫调节、抗炎和代谢特性。这些特性共同解释了ELT在广泛适应症中的有效性；此外，它们还表明ELT在不同的、具有挑战性的临床场景中可能有效。我们回顾了ELT在各种疾病中的扩展作用机制，旨在进一步探索其全部潜力，并推测新的、引人入胜的适应症。
